The anti-NC and anti-ORF4 magnitudes were, on average, significantly higher in non-cancer individuals, while the anti-ORF1 magnitudes were significantly higher in cancer patients (p = 0.031, p = 0.043, and p = 0.040, respectively) (Figure 3C). This evidence concerns the gene CTTNBP2 and cancer.